Granules India's Gagillapur Plant Gets 11 US FDA Observations
Granules India’s Gagillapur facility has received 11 US FDA observations, with none related to data integrity or cross-contamination.
Granules India Gagillapur Facility | 02/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy